Navigation vs Usual Care for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC
NCT04030130 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 176
Last updated 2025-01-29
Summary
Head and neck cancer squamous cell carcinoma (HNSCC) is a disease with poor survival, especially for African Americans, despite intense treatment including surgery, radiation, and chemotherapy. Delays between surgery and the start of postoperative radiation therapy (PORT) are common, cause excess mortality, and contribute to worse survival in African Americans. Our research team has developed NDURE (Navigation for Disparities and Untimely Radiation thErapy), a novel theory-based patient navigation (PN) intervention to decrease delays and racial disparities starting PORT. In this single-site, open label, parallel-group, randomized controlled trial of adults with surgically-managed, locally advanced HNSCC, will be randomized to NDURE versus usual care to assess the preliminary clinical impact of NDURE on delays and racial disparities starting PORT after surgery for HNSCC. The investigators will collect information about the rate of PORT delay, racial disparities in the rate of PORT delay, and completion rate of key cancer care processes. Participants will also complete validated questionnaires at baseline and post-intervention to understand the theoretical constructs underlying NDURE . Post-intervention, patients and providers will undergo interviews to obtain in-depth understanding of the content, format, timing, and delivery of NDURE to optimize the intervention in preparation for a future multi-site study. NDURE could provide the first effective intervention to improve the delivery of timely, equitable PORT after HNC surgery, thereby improving survival for patients with HNC, decreasing racial disparities in mortality, and developing new standards of clinical care.
Conditions
- Squamous Cell Carcinoma of Head and Neck
Interventions
- BEHAVIORAL
-
NDURE
NDURE is a theory-based, multi-level Patient Navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system- (care coordination), interpersonal- (social support), and individual- (Health Belief Model; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, improve cancer care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (\~3 months).
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Medical University of South Carolina
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-05-19
- Primary Completion
- 2023-12-11
- Completion
- 2024-01-29
Countries
- United States
Study Locations
More Related Trials
-
Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT03815903 ·Status: RECRUITING ·Phase: PHASE3
-
Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma
NCT06218004 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT05527782 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
NCT01312350 ·Status: COMPLETED ·Phase: PHASE2
-
TPF Induction With Concomitant Chemoradiation to Treat Patients With Head and Neck Cancer
NCT00774319 ·Status: UNKNOWN ·Phase: PHASE2
-
Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
NCT00509665 ·Status: COMPLETED ·Phase: PHASE2
-
Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN
NCT03726775 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Prospective Randomized Controlled Study of Radiotherapy and the Concurrent Three-week and Single-week TP Chemotherapy for Advanced Cervical Squamous Cell Carcinoma and the Correlation Between HPV Classification and Sensitivity.
NCT04588090 ·Status: UNKNOWN ·Phase: NA
-
A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab
NCT01435252 ·Status: COMPLETED ·Phase: PHASE2
-
Real-world Analysis on the Efficacy and Safety of Neoadjuvant Therapy for Head and Neck Squamous Cell Carcinoma (neoHNSCC)
NCT06011993 ·Status: UNKNOWN
-
Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer
NCT01372111 ·Status: UNKNOWN ·Phase: PHASE2
-
Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer
NCT01313390 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC
NCT02047201 ·Status: COMPLETED ·Phase: PHASE2
-
Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT02997332 ·Status: TERMINATED ·Phase: PHASE1
-
Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer
NCT03051906 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck
NCT02110992 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer
NCT00148122 ·Status: COMPLETED ·Phase: PHASE2
-
Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck
NCT02776137 ·Status: COMPLETED ·Phase: PHASE2
-
Chemo-embolization for Head and Neck Cancer
NCT04595981 ·Status: WITHDRAWN ·Phase: PHASE2
-
S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00054054 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer
NCT00713219 ·Status: COMPLETED ·Phase: PHASE2
-
A Retrospective Analysis of Neck Dissection Following Complete Response to Chemoradiation in HNSCC
NCT00483821 ·Status: COMPLETED
-
High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer
NCT00052429 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Adaptive Radiotherapy for Head and Neck Cancer
NCT03096808 ·Status: COMPLETED ·Phase: PHASE2
-
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00281840 ·Status: COMPLETED ·Phase: PHASE2